Alcami Corp.

Welcome to Endpoints News ’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Cell therapy CDMO BioCentriq has appointed Syed Husain as its new CEO, who recently was the chief commercial officer at Resilience. Prior to Resilience, Husain held roles at Alcami, Emergent BioSolutions and Lonza, according to a Thursday announcement. Sanofi and AstraZeneca have secured FDA approval for a new manufacturing filling line to boost production capacity for their respiratory syncytial virus vaccine, according to a Monday release. Sanofi is already shipping 50 mg and 100 mg lots of Beyfortus to US private healthcare providers and the Centers for Disease Control and Prevention for its initiative called Vaccines for Children. Earlier this year, Sanofi warned Beyfortus would be in short supply in the first quarter 2024 and was honed in on boosting manufacturing capacity. Gavi, the Vaccine Alliance, has purchased 500,000 doses of Bavarian Nordic’s mpox vaccine for use in Africa, the consortium said Wednesday. The UK government has also purchased 150,000 doses of Bavarian Nordic’s mpox vaccine for local use. The UK is prioritizing vaccinations for men who have sex with men, healthcare workers, specialist healthcare and humanitarian workers, and those in close contact with someone infected with mpox, according to a Tuesday announcement. Lonza has opened a new facility at its site in Colmar, France, dubbed the “Innovaform Accelerator,” the company said Thursday . The new facility will develop oral and pulmonary drug delivery systems. Thermo Fisher Scientific’s clinical research and analytical arm, PPD, is expanding its laboratory services with a new 29,000-square-foot bioanalytical lab. It will be located at the GoCo Health Innovation City in Gothenburg, Sweden. The new lab will cover small and large molecules as well as biomarkers, the company said Wednesday. Cell therapy CDMO Kincell Bio has secured a multi-year partnership with an unnamed customer, the manufacturer said Monday. Under the deal, Kincell will make the client’s cell therapy for degenerative disease at its facility in Gainesville, FL. CDMO Recipharm has expanded its oral solid development site in Zwickau, Germany, by adding three manufacturing suites for blending, tableting and filling capsules. The expansion will be operational by the first quarter of 2025, the company said Monday. Richter BioLogics has opened a new manufacturing factory in Bovenau, Germany, according to a Monday release. The 10,000-square-meter facility houses clinical and commercial manufacturing of protein and DNA-based therapies, among others.

Central North Carolina pharma storage facility now offers extensive cold and stability conditions plus full suite of material support services DURHAM, N.C., July 23, 2024 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), has significantly expanded the cold, stability, and custom storage options at its new 65,000 ft2 state-of-the-art pharma storage facility in Garner. With a prime location near the Research Triangle Park (RTP) biotech and pharma hub, the best-in-class facility offers diverse, customizable, scalable, long-term storage conditions for temperature-sensitive vaccines, biopharma therapies, cell banks, tissues, pharmaceutical compounds, raw materials, components and medical devices. Alcami's new state-of-the-art pharma storage facility in Garner, NC.

DURHAM, N.C., Feb. 8, 2024 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the strategic expansion of its sterile fill/finish manufacturing capacity with the addition of a new sterile fill/finish line with isolator and two lyophilizers at its existing Charleston, SC manufacturing campus. The new state-of-the-art, fully automated GMP sterile filling line offers the flexibility to fill liquid and freeze-dried vials under isolator technology to minimize the potential for contamination, providing the capacity and scalability for clinical and commercial needs and is fully integrated with the company's network of formulation development, packaging / labeling, lab services and pharma storage and services facilities. The expansion aims to meet growing industry demands for onshore sterile fill/finish capabilities amidst supply constraints, industry consolidation and tightening capacity as the pipeline of biologics and specialty therapeutics continues to grow. "In a tight market, capacity is at a premium and conditions favor those with immediate capabilities. As Alcami continues to align with the future of pharma and biotech, we're meeting increased demand with this new sterile fill/finish manufacturing line on our Charleston campus," said Bill Humphries, CEO of Alcami. "Because Alcami offers integrated services through every stage of the development lifecycle, we can help clients mitigate supply chain risks by providing onshore, streamlined and cost-efficient solutions. We're committed to offering the latest manufacturing, analytical and storage capabilities and plan continued expansion of our manufacturing capacity to help bring our clients' innovative therapeutics to patients." About Alcami Alcami is a contract development and manufacturing organization headquartered in North Carolina with over 40 years of experience advancing products through every stage of the development lifecycle. Alcami serves pharmaceutical and biotech companies of all sizes for small molecules and biologics, providing customizable and innovative solutions for analytical development, clinical to commercial sterile and oral solid dose drug product manufacturing, packaging, microbiology, GMP pharma storage, environmental monitoring, and pharmaceutical support services. Alcami's private equity ownership includes GHO Capital, The Vistria Group, and Ampersand Capital Partners. For more information, please visit alcami.com. SOURCE Alcami Corporation